XL-protein GmbH has granted Grifols a worldwide License, Development and Commercialization Agreement for a novel, long-acting biopharmaceutical product. This agreement leverages XL-protein's proprietary, clinical-stage PASylation® technology.
The PASylation® technology is designed to extend the circulation of Grifols therapeutics, which could pave the way for more effective and long-lasting treatments for patients. XL-protein will actively support preclinical development activities under the terms of the collaboration.
Under the agreement, Grifols will be entitled to further developing, manufacturing, and marketing the PASylated-enhanced biologic, with worldwide exclusive marketing rights. XL-protein will receive an upfront payment, payments for preclinical, clinical, regulatory, and commercial milestones, and tiered royalties on sales from marketed therapeutics.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.